Member Info for Vertizea-Sun

I'm going back to bed.

Orphan Drug Designation is an American "product" so it obviously makes sense to undertake the testing in the US. Does the MHRA even have an equivalent? I doubt it.

Yes Timster....it's very sad but AS warned the government.....it's their call. His January letter to The Times editor spells it out :

Sir, Emma Duncan’s column about problems facing UK life sciences companies (Jan 27) is right that lack of investment drives pioneering British businesses to turn to the United States for scale-up funding. Despite our world-leading expertise, UK biotech unicorns are rare. In the past four years 11 UK biotechs have chosen to make their initial public offering in the US. Why are we so bad at holding on to long-term value generated by our innovative science? There are many factors but in my view it’s primarily due to overburdensome regulation, compounded by a paucity of expert analysts to guide risk-averse UK investment managers.

The Retail Distribution Review (RDR) and the EU generated Markets in Financial Instruments Directive 11 (MiFID 11) both had dire unintended consequences for high-growth, high-risk companies. These oppressive pieces of regulation put smaller investment banks off high-risk stocks, restricting the UK public markets opportunity for many life-sciences companies, giving them little choice but to seek funding abroad.

Jeremy Hunt wants science innovators to come to Britain “to make their visions happen”.

Admirable aspiration, but we need a smarter strategy to scale our own life sector if we’re to reap the potentially substantial rewards. A good start would be relaxing the constraints of RDR and MiFID 11).

Dr Alastair Smith

CEO, Avacta Group

So that's where Wyndrum gets his essays.

C7 is a possibility but a Business Development Officer available to begin on the 18th September says otherwise.....or not?

A lot of salary in poor old UK.....not so much in the US of A.

Qué?

Very plausible......fluent in French and good German.

Same old computer problem....s*** in - s*** out. Although AI is good at imaging.

Who is Alan?

A truly accurate Covid test would very quickly develop a big professional market......the world's navies-especially submarines and high seas fleets, offshore rig crews, specialised lab crews, etc,etc. And there would be no real quibbling about the price.....if it works. Over to you.... Affimer.

To be exploited by the new Business Development Officer.......a position intended to begin two weeks tomorrow.

NY in my opinion. It's an unusual amount but more or less $200,000.

"The affimer is going nowhere near a commercialised Dx device"

Bet you a fiver you are wrong. Launch, Corbis and dozens of expensive bods in Wetherby says otherwise.

I'll guess..... Old Boy's Network

Takeda's holding WAS reported as a nominal 50,000 shares....about two years ago. Interestingly it was also reported to be Takeda's only outside investment.

"Myles’s updates sure don’t have the effect on the share price"

Well - the past is a foreign country and all that and that means nothing will have an effect on the share price unless it's an RNS thick with £/$ and multiple 0's. Nothing else will have a real impact....this is a different era and 2020 is history. I believe pre | CISION works and I also believe that it is hard baked into the share price so an announcement on Cohort 6 will be just Traders Delight.

However, an RNS with dollar signs has to appear before Christmas because by then the Avacta board will want sight of management's plans for funding in the last half of next year.

And that's a fact.

A further update from MM but probably best I don't post it. I worry about your blood pressure.

It has been a long wait but two recent developments indicate a completely different company by Christmas:

1: Shaun Chilton agreeing to join the board. As the boss of Clinigen he was an acknowledged world expert in the management of pharmaceutical companies and after selling that company for over a billion and retiring his in-box would have over-flowed with NED's. Choosing Avacta is no accident. He intends to build on his success as people like him tend to do.

2: Second of course is a Business Development Officer......which likely flows directly from June's appointment of SC. And where do the Koreans fit into all of this?

Https://www.bachbioscience.com

William Bachovchin's own web site identifies three research programmes and the first is TMAC with Avacta getting the honourable call-out although he doesn't mention pre | CISION.....just linking AVA6000 & TMAC:

"1.Tumor Micro-enviroment Activated Drug (TMACs).

A platform technology—currently focused on using FAP as the tumor specific enzyme for activation.

Example: AVA6000 releases Doxorubicin. Currently licensed to Avacta Life sciences and is in phase 1 human clinical trials."

Affimers are not mentioned either but I still believe they are pivotal to a successful TMAC. Why would Bachovchin bother with Avacta otherwise?

The other two programmes are both licensed to POINT Biopharma which is not bad for a company that was only founded 4 years ago but already has 130 employees and 180,000 sq feet of Indianapolis manufacturing space.

The second programme seems to be Bachovchin covering his options as this is FAP linked binding as opposed to Avacta's FAP linked cleaving.

"2.Tumor Microenvironment Localized drugs. (TMELDs)."

The third programme is Can-SEEK.

POINT Biopharma are not hanging around.